6/28/23, 12:14 AM COLOR Pathway Feedback Search Clinical Topics Home Studies COLOR COLOR Disease Hand osteoarthritis Trial question What is the role of colchicine in adults with symptomatic hand OA? Study design Single center Double blinded RCT Population Characteristics of study participants 69.0% female N = 100 31.0% male 100 patients (69 female, 31 male) Inclusion criteria: adults with symptomatic hand OA and finger pain of at least 40 mm on a 100 mm VAS Key exclusion criteria: other known medical diseases that may affect joints; known cutaneous deposition diseases; known blood dyscrasias and coagulation disorders; known malignancy Interventions N=50 colchicine (an oral dose of 0.5 mg BID for 12 weeks) N=50 placebo (matching placebo tablet BID for 12 weeks) Primary outcome Reduction in finger pain at week 12 13.9 mm 13.9 13.5 10.4 mm https://web.pathway.md/studies/recauv5XQYAo6X2k0 1/2 6/28/23, 12:14 AM COLOR Pathway 7.0 mm 3.5 mm No significant difference 0.0 mm Colchicine Placebo No significant difference in reduction in finger pain at week 12 (13.9 mm vs. 13.5 mm; AD 0.4 mm, 95% CI -6.7 to 7.6) Safety outcomes No significant difference in adverse and serious adverse events. Conclusion In adults with symptomatic hand OA and finger pain of at least 40 mm on a 100 mm VAS, colchicine was not superior to placebo with respect to reduction in finger pain at week 12. Reference Anna D ssing, Prof Marius Henriksen, Karen Ellegaard et al. Colchicine twice a day for hand osteoarthritis (COLOR): a double-blind, randomised, placebo-controlled trial. Lancet Rheumatol. 2023 Apr 4;5(5):E254-E262. Open reference URL https://web.pathway.md/studies/recauv5XQYAo6X2k0 2/2